Coverage
-
January 14, 2013
A Pennsylvania federal judge on Monday signed off on a $21.5 million settlement between GlaxoSmithKline PLC and employee benefit plans in a class action alleging the pharmaceuticals giant filed sham patent suits to intentionally delay generic competition to its antidepressant Wellbutrin SR.
5 other articles on this case.
View all »